LKT Labs

Biochemicals for Life Science Research

Dasatinib

Dasatinib

Product ID D023721
Cas No. 302962-49-8
Purity ≥99%
Product Unit SizeCostQuantityStock
25 mg $47.80 In stock
100 mg $88.60 In stock
250 mg $238.60 In stock
Bulk Quote

Quicklinks

Description

Dasatinib is an anticancer chemotherapeutic compound that inhibits Abl, PDGFR, ephrin receptors, Src, c-Kit, and other Src-family kinases (LCK, HCK, FYN, and others). Dasatinib is clinically used to treat chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL); in acute myelogenous leukemia (AML) cells, dasatinib induces myeloid differentiation and autophagy. Dasatinib also displays antiviral activity, preventing dengue virus infection through its inhibition of FYN kinase.

Product Info

Cas No.

302962-49-8
Purity

≥99%
Formula

C22H26ClN7O2S
Formula Wt.

488.01
IUPAC Name

N-(2-Chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl}amino)-1,3-thiazole-5-carboxamide
Synonym

BMS354825, BMS-354825, Sprycel

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D023721 MSDS PDF
Info Sheet

D023721 Info Sheet PDF

References

Xie N, Zhong L, Liu L, et al. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. Biochem Pharmacol. 2014 May 1;89(1):74-85. PMID: 24607273.

de Wispelaere M, LaCroix AJ, Yang PL. The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase. J Virol. 2013 Jul;87(13):7367-81. PMID: 23616652.

Montero JC, Seoane S, Ocaña A, et al. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011 Sep 1;17(17):5546-52. PMID: 21670084.

Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006 Nov 16;49(23):6819-32. PMID: 17154512.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • O7218

    Oseltamivir Phosphate

    Viral neuraminidase inhibitor, potential MAO-A ...

    ≥98%
  • M1979

    Methyl Salicylate

    Ester found in Spiraea, Betula, and Gaultheria;...

    ≥98%
  • C4517

    Clenbuterol Hydrochloride

    β2-adrenergic agonist.

    ≥98%
  • B0397

    BAY80-6946 Hydrochloride

    pan-PI3K inhibitor

    ≥98%
  • L9874

    L-(+)-Lysine Monohydrate

    Non-endogenous essential amino acid found in me...

    ≥95%
  • G4797

    GLYX-13 Trifluoroacetate

    Peptide; NMDA partial agonist.

    ≥98%
  • C9809

    Cyclopiazonic Acid

    SERCA inhibitor.

    ≥98%, TLC
  • A2044

    Aflatoxin B1

    Mycotoxin produced by species of Aspergillus; D...

    ≥98%
  • A6925

    L-Arginine Ethyl Ester Dihydrochloride

    Arginine source used to increase NO production....

    ≥98%
  • A4933

    Amifostine Trihydrate

    Thiol prodrug, antioxidant.

    ≥98%
  • O4532

    Oligomycin B

    Macrolide; F1F0 ATP synthase inhibitor.

    ≥97%, TLC, HPLC
  • A5045

    Amlodipine

    Dihydropyridine, FIASMA; L-type Ca2+ channel bl...

    ≥98%
  • A971334

    Azilsartan

    Sartan

    ≥98%
  • S5868

    Sorafenib

    c-Raf, Ret, VEGFR2 inhibitor, potential STAT3/5...

    ≥98%
  • C1718

    Cepharanthine, 95%

    Alkaloid found in Stephania.

    ≥95%
  • T1953

    Tenovin-3

    Potential p53 activator or SIRT2 inhibitor.

    ≥98%
  • L589921

    Loxapine Succinate

    D2 and D4 dopamine receptor inhibitor.

    ≥99%
  • A4940

    6-Aminonicotinamide

    G6PDH inhibitor.

    ≥98%
  • P2859

    Phosphate Acceptor Peptide

    PKC and S6 kinase substrate.

    ≥95%
  • M1676

    Methotrexate Hydrate

    DHF reductase inhibitor.

    ≥98%